At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
mRNA-transfected autologous dendritic cells +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy
In Brief
A Phase 2 clinical trial evaluating mRNA-transfected autologous dendritic cells and autologous dendritic cells with no mRNA transfection for HIV-1 Infection and HIV Infections. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection, HIV Infections
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartAug 2009
Primary CompletionDec 2013
TodayJul 2026
First PostedFeb 2, 2009
Enrollment StartAug 1, 2009
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.4 years ago
Interventions
mRNA-transfected autologous dendritic cellsbiological
Injections will be administered intradermally at weeks 0, 2, 6 and 10.
autologous dendritic cells with no mRNA transfectionbiological
Injections will be administered intradermally at weeks 0, 2, 6 and 10.